calcitonin and Osteoporotic-Fractures

To analyze and evaluate the clinical efficacy of the combination of locking plate and anti-osteoporosis drug for the patients with senior osteoporotic proximal humerus fractures. 120 patients with senior osteoporotic proximal humerus fractures were selected as research objects. According to the differences of treatment options, they were divided into two groups, i.e., 60 patients in observation group accepting the treatment of combination of locking plate and anti-osteoporosis drug, the other 60 patients in the control group accepting simple locking plate treatment. The treatment effect and final result between the two groups were compared. The follow-up result showed that the average fracture healing time of observation group was (94.5±4.2) days, with excellent treatment rate reaching to 93.33% (56/60); the average fracture healing time of control group was (116.5±3.8) days, with excellent treatment rate of 75% (45/60). The intergroup different was of statistical significance, wherein p<0.05. The treatment efficacy of the combination of locking plate and anti-osteoporosis drug for senior osteoporotic proximal humeral fractures is faster and more precise, which is worth being applied in clinical practice.

Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Plates; Calcitonin; Calcitriol; Calcium Carbonate; Female; Fracture Healing; Humans; Humerus; Male; Middle Aged; Osteoporotic Fractures; Time Factors; Treatment Outcome

This randomized, double-blind, placebo-controlled phase III study was conducted to assess the efficacy and safety of oral calcitonin (SMC021) for the treatment of postmenopausal osteoporosis. A total of 4665 postmenopausal women with osteoporosis were randomized 1:1 to receive calcium and vitamin D plus either SMC021 tablets (0.8mg/d) or placebo for 36months. The primary endpoint was the proportion of patients with a new vertebral fracture. The two groups were well balanced at baseline with regards to demographic and clinical data. No effect of SMC021 on preventing new vertebral fractures was observed, nor was any effect seen on new hip or non-vertebral fractures. Women receiving SMC021 had a mean 1.02% (±0.12%) increase in lumbar spine bone mineral density (BMD) compared with a mean 0.18% (±0.12%) increase in the placebo group by the end of the study (p<0.0001). Similarly, small increases in BMD were observed at the femoral neck and hip in both groups. Levels of the biomarkers of bone turnover, urinary CTX-I and CTX-II, were 15% lower in the SMC021 group than in the placebo arm at 12 and 24months, but not at 36months. No change in quality of life between groups, assessed by the Qualeffo-14 questionnaire, was observed in either group between baseline and month 36. Pharmacokinetics analysis confirmed exposure to SMC021, but the drug levels were markedly lower than expected. Approximately 92% of subjects in each treatment group experienced an adverse event (AE), the majority of which were mild or moderate in intensity. AEs associated with SMC021 were primarily of gastrointestinal origin and included nausea, vomiting and abdominal pain, as well as hot flushes which were the reason for the slightly higher drop-out rate in the active treatment arm compared to placebo. The number of severe AEs was low in both groups. Thirty-five deaths were reported but none were considered treatment-related. Due to the lack of efficacy in preventing fractures, the development of the orally formulated calcitonin was terminated despite the promising results in earlier studies.

Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Remodeling; Calcitonin; Calcium; Demography; Double-Blind Method; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Placebos; Quality of Life; Risk Factors; Treatment Outcome; Vitamin D

To investigate the analgesic effect of nasal salmon calcitonin on the post-fracture period of distal radius fracture.. In this prospective randomized double-blind study, forty-one postmenopausal women with a recent distal radius fracture treated conservatively were randomly assigned to receive either 200 IU of intranasal salmon calcitonin or placebo daily for 3 months following fracture. The assessment of the patient's pain was recorded using the Visual Analogue Scale (VAS).. The average age of the calcitonin group was 67.11 (SD, ±8.68) years and 64.91 (SD, ±7.48) of the placebo group. In the calcitonin group, the mean VAS score improved from 4.05 to 0.53 while in the placebo group from 3.36 to 0.32. A higher decrease of VAS score during the first post-fracture period was observed in the calcitonin group.. In the study, there is a statistically significant calcitonin mediated analgesic effect in the immediate post fracture period (at 10 days) when compared to placebo group. These results are in accordance with literature referring to the analgesic effect of calcitonin in the acute osteoporotic vertebral compression fracture. Thus calcitonin administration could be recommended to a short term course in acute osteoporotic conservatively treated distal radius fractures.

Topics: Administration, Intranasal; Aged; Analgesics; Calcitonin; Double-Blind Method; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Pain; Pain Measurement; Prospective Studies; Radius Fractures; Treatment Outcome

The effect of an investigational oral calcitonin tablet upon bone mineral density (BMD) of the spine was investigated in postmenopausal women with low bone mass and at increased risk of fracture. Compared to placebo, calcitonin tablets increased lumbar spine BMD. This agent may provide an additional choice for patients.. An investigational oral salmon calcitonin preparation was previously shown to increase lumbar spine BMD in postmenopausal women with osteoporosis. Our objective was to evaluate the use of this agent in postmenopausal women with low bone mass and at increased fracture risk but not meeting BMD criteria for osteoporosis.. Treatment-naïve women were randomized to receive oral recombinant salmon calcitonin tablets or placebo once daily for 1 year. Dual-energy X-ray absorptiometry was performed at baseline and at study weeks 28 and 54. CTx-1, a bone resorption marker, was obtained at the same time points. Subjects returned periodically for tolerability assessment and adverse event (AE) recording.. One hundred twenty-nine women in the USA were randomized, 86 to calcitonin and 43 to placebo. Calcitonin recipients experienced a significant increase from baseline in lumbar spine BMD; the difference compared with placebo was significant. Dosing at bedtime or with dinner was equally effective. CTx-1 was suppressed in calcitonin recipients but not in placebo subjects. Gastrointestinal AEs were common, but the overall safety profile was comparable between groups.. Oral calcitonin may provide a useful therapeutic alternative for some women with low bone mass.

Topics: Absorptiometry, Photon; Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; Collagen Type I; Double-Blind Method; Female; Femur Neck; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Single-Blind Method; Treatment Outcome

Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Cholecalciferol; Humans; Lumbosacral Region; Male; Osteoporosis; Osteoporotic Fractures